Parenteral dosage form of carboplatin

US12508269B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12508269-B2
Application numberUS-201917768021-A
CountryUS
Kind codeB2
Filing dateAug 30, 2019
Priority dateAug 31, 2018
Publication dateDec 30, 2025
Grant dateDec 30, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.

First claim

Opening claim text (preview).

We claim: 1 . A parenteral dosage form having an infusion container filled with an aqueous solution in a volume ranging from 40 ml to 500 ml, the aqueous solution comprising 1 mg/ml to 2 mg/ml of carboplatin and 0.02 mg/ml to 2.0 mg/ml of ammonium sulphate, wherein the aqueous solution contains known impurity of 1,1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature. 2 . The parenteral dosage form of claim 1 , wherein the solution comprises 1 mg/ml of carboplatin and a dissolved oxygen content in the range of about 5 ppm to 50 ppm. 3 . The parenteral dosage form of claim 2 , wherein the ammonium sulphate is in an amount ranging from 0.2 mg/ml to 2.0 mg/ml and the dissolved oxygen content is in an amount ranging from about 5 ppm to 10 ppm. 4 . The parenteral dosage form of claim 2 , wherein the dissolved oxygen content is in an amount ranging from about 10 ppm to 50 ppm. 5 . The parenteral dosage form of claim 3 , wherein the volume of the aqueous solution is 50 ml. 6 . The parenteral dosage form of claim 1 , wherein the aqueous solution is free of dextrose. 7 . A parenteral dosage form of claim 1 , wherein the solution comprises 2 mg/ml of carboplatin and a dissolved oxygen content in the range of about 5 ppm to 50 ppm. 8 . The parenteral dosage form of claim 7 , wherein the dissolved oxygen content is in an amount ranging from about 10 ppm to 50 ppm. 9 . The parenteral dosage form of claim 7 , wherein the ammonium sulphate is in an amount ranging from 0.5 mg/ml to 2.0 mg/ml and the dissolved oxygen content is an amount ranging from about 5 ppm to 10 ppm. 10 . The parenteral dosage form of claim 8 , wherein the volume of the aqueous solution is 50 ml. 11 . The parenteral dosage form of claim 1 , wherein the aqueous solution is free of chloride salts. 12 . The parenteral dosage form of claim 1 , wherein the infusion container is a perfusion bag, an infusion bag, or a flexible pouch. 13 . The parenteral dosage form of claim 12 , wherein the parenteral dosage form has been subjected to autoclaving. 14 . The parenteral dosage form of claim 1 , wherein the aqueous solution has a pH in the range of about 4.0 to 6.0. 15 . The parenteral dosage form of claim 1 , wherein the aqueous solution has a pH in the range of 4.5 to 5.5. 16 . The parenteral dosage form of claim 1 , wherein the aqueous solution is free of dextrose and sodium chloride. 17 . The parenteral dosage form of claim 1 , wherein the aqueous solution is free of one or more of chelating agents, preservatives, buffering or pH adjusting agents, solubilizers, co-solvents, and osmogens. 18 . The parenteral dosage form of claim 1 , wherein the aqueous solution is a ready-to-administer aqueous solution. 19 . The parenteral dosage form of claim 2 , wherein the volume of the aqueous solution is 40 ml, 60 ml, 80 ml, 100 ml, 150 ml, 200 nl, 300 ml, 330 ml, 360 ml, 390 ml, 430 ml, 470 ml, or 500 ml.

Assignees

Inventors

Classifications

  • Inorganic compounds · CPC title

  • Solutions {(composition of solutions A61K47/00)} · CPC title

  • Compounding apparatus specially for enteral or parenteral nutritive solutions (bottling liquids B67C) · CPC title

  • Bag-type containers · CPC title

  • Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12508269B2 cover?
A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.
Who is the assignee on this patent?
Sun Pharmaceutical Ind Ltd
What technology area does this patent fall under?
Primary CPC classification A61K31/555. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).